Skip to main content
Premium Trial:

Request an Annual Quote

UK Firm Sensyne Health Inks $652K Deal to Pilot AI Technology With SARS-CoV-2 Lateral Flow Tests

NEW YORK ─ Oxford, UK-based Sensyne Health on Friday said it has inked a £470,000 ($652,500) agreement with the UK Department of Health & Social Care to conduct the second stage of a pilot study that uses its MagnifEye system with COVID-19 lateral flow diagnostic tests.

The MagnifEye system is a software application available as a smartphone app and web application that uses a cloud-based deep-learning algorithm to automate the reading and analysis of different diagnostic test results including for lateral flow tests.

MagnifEye trains users to administer a lateral flow test and interpret the test result, and provides a digital certificate that validates the training, the test result, and the associated health status, enabling frequent testing for COVID-19 and a range of other conditions, Sensyne said.

The agreement with the Department of Health & Social Care follows an announcement in February that Sensyne had signed an exclusive license and development agreement with Excalibur Healthcare Services to apply MagnifEye for use with the Excalibur SARS COV-2 rapid antigen lateral flow test.

Excalibur said in a separate statement that the integration of Sensyne's AI algorithms enables it to quickly detect the presence of low viral loads of SARS-COV-2.